NCT06241183 Famotidine and Antacids for Treatment of Dyspepsia
| NCT ID | NCT06241183 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Stony Brook University |
| Condition | Dyspepsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-11-09 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2023-11-09 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Eligibility Criteria
Inclusion Criteria: 1. Subject Age ≥ 18 years of age 2. Patient diagnosed with dyspepsia 3. Present at the ED with upper abdominal pain score of at least 3 Exclusion Criteria: 1. Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine 2. Moderate to Severe Renal Insufficiency (precaution) 3. Kidney Failure 4. Pregnant or Nursing 5. Verbal pain score less than 3 6. Inability to tolerate oral medications 7. Bowel Obstruction 8. Proton pump inhibitor within 2 hours of study treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06241183 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dyspepsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06241183 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06241183 currently recruiting?
Yes, NCT06241183 is actively recruiting participants. Contact the research team at adam.singer@stonybrookmedicine.edu for enrollment information.
Where is the NCT06241183 trial being conducted?
This trial is being conducted at Stony Brook, United States.
Who is sponsoring the NCT06241183 clinical trial?
NCT06241183 is sponsored by Stony Brook University. The trial plans to enroll 80 participants.